[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT201400038A - Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf - Google Patents

Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf

Info

Publication number
GT201400038A
GT201400038A GT201400038A GT201400038A GT201400038A GT 201400038 A GT201400038 A GT 201400038A GT 201400038 A GT201400038 A GT 201400038A GT 201400038 A GT201400038 A GT 201400038A GT 201400038 A GT201400038 A GT 201400038A
Authority
GT
Guatemala
Prior art keywords
inhibitor
mapk
compositions
p13kbeta
methods
Prior art date
Application number
GT201400038A
Other languages
English (en)
Inventor
Carlos García-Echeverría
Loïc Vincent
Angela Virone-Oddos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400038A publication Critical patent/GT201400038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES QUE COMPRENDEN AL MENOS UN INHIBIDOR DE LA VÍA MAPK INCLUYENDO INHIBIDORES DE MEK Y DE LA RAF Y AL MENOS UN INHIBIDOR DE PI3K, Y TAMBIÉN A LOS USOS DE LOS MISMOS PARA EL TRATAMIENTO DE CÁNCER.
GT201400038A 2011-09-16 2014-03-03 Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf GT201400038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11306172A EP2570127A1 (en) 2011-09-16 2011-09-16 Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors

Publications (1)

Publication Number Publication Date
GT201400038A true GT201400038A (es) 2014-12-16

Family

ID=46851503

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400038A GT201400038A (es) 2011-09-16 2014-03-03 Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf

Country Status (25)

Country Link
US (1) US20140275078A1 (es)
EP (2) EP2570127A1 (es)
JP (1) JP2014530181A (es)
KR (1) KR20140062143A (es)
CN (1) CN103889418A (es)
AR (1) AR087902A1 (es)
AU (1) AU2012307309A1 (es)
BR (1) BR112014005839A2 (es)
CA (1) CA2847091A1 (es)
CL (1) CL2014000606A1 (es)
CO (1) CO6910192A2 (es)
CR (1) CR20140102A (es)
DO (1) DOP2014000046A (es)
EA (1) EA201490638A1 (es)
EC (1) ECSP14013244A (es)
GT (1) GT201400038A (es)
IL (1) IL231212A0 (es)
MA (1) MA35615B1 (es)
MX (1) MX2014003223A (es)
NI (1) NI201400020A (es)
PE (1) PE20141035A1 (es)
SG (1) SG11201400380XA (es)
TN (1) TN2014000086A1 (es)
UY (1) UY34341A (es)
WO (1) WO2013037943A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
BR112015025101A2 (pt) * 2013-04-05 2017-07-18 Sanofi Sa composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo
US10111897B2 (en) 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity
US10028958B2 (en) 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR101950094B1 (ko) 2017-07-28 2019-02-19 이성재 보릿대 공예품 제작방법
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
FR2951169B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
EA021088B1 (ru) 2009-07-02 2015-04-30 Санофи Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования akt (pkb)

Also Published As

Publication number Publication date
EP2755653A1 (en) 2014-07-23
WO2013037943A8 (en) 2013-07-18
JP2014530181A (ja) 2014-11-17
AR087902A1 (es) 2014-04-23
SG11201400380XA (en) 2014-04-28
PE20141035A1 (es) 2014-09-04
MX2014003223A (es) 2014-06-05
EA201490638A1 (ru) 2014-08-29
BR112014005839A2 (pt) 2017-03-28
CA2847091A1 (en) 2013-03-21
WO2013037943A1 (en) 2013-03-21
UY34341A (es) 2013-04-05
CL2014000606A1 (es) 2014-11-07
CN103889418A (zh) 2014-06-25
TN2014000086A1 (en) 2015-07-01
KR20140062143A (ko) 2014-05-22
EP2570127A1 (en) 2013-03-20
NI201400020A (es) 2014-04-23
US20140275078A1 (en) 2014-09-18
ECSP14013244A (es) 2014-07-31
DOP2014000046A (es) 2014-07-15
MA35615B1 (fr) 2014-11-01
AU2012307309A1 (en) 2014-04-03
IL231212A0 (en) 2014-04-30
CR20140102A (es) 2014-05-07
CO6910192A2 (es) 2014-03-31

Similar Documents

Publication Publication Date Title
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CR20150571A (es) Compuestos y composiciones terapéuticos
CR20130267A (es) Inhibidores de nampt y rock
ECSP14013223A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
CR20150316A (es) Compuestos y sus métodos de empleo
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
DOP2014000253A (es) Inhibidores del nampt
NI201400042A (es) 2 - tiopirimidinonas
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
GT201300148A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek